Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

PROCEPT BioRobotics (PRCT) Research & Development (2020 - 2026)

PROCEPT BioRobotics has reported Research & Development over the past 7 years, most recently at $21.5 million for Q1 2026.

  • Quarterly Research & Development rose 30.87% to $21.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $76.3 million through Mar 2026, up 16.34% year-over-year, with the annual reading at $71.3 million for FY2025, 14.41% up from the prior year.
  • Research & Development was $21.5 million for Q1 2026 at PROCEPT BioRobotics, up from $19.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $21.5 million in Q1 2026 and troughed at $5.0 million in Q1 2022.
  • The 5-year median for Research & Development is $14.5 million (2023), against an average of $13.7 million.
  • Year-over-year, Research & Development surged 114.27% in 2023 and then grew 0.75% in 2025.
  • A 5-year view of Research & Development shows it stood at $9.7 million in 2022, then surged by 49.72% to $14.5 million in 2023, then rose by 3.93% to $15.1 million in 2024, then grew by 26.48% to $19.1 million in 2025, then grew by 12.64% to $21.5 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Research & Development are $21.5 million (Q1 2026), $19.1 million (Q4 2025), and $18.2 million (Q3 2025).